{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Mangalam Drugs and Organics Ltd
Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 1.88% Gain — Buyers Queue, Sellers Absent
At Rs 29.58, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 5% on 15 Jun 2026, with buyers queuing and no sellers willing to part with shares.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 08 June 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall market standing.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 May 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Mangalam Drugs and Organics Ltd Locks at Lower Circuit With 5% Loss — Sellers Queue, No Buyers in Sight
At Rs 28.46, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 18 May 2026, with unfilled sell orders and a frozen price.
Are Mangalam Drugs and Organics Ltd latest results good or bad?
Mangalam Drugs and Organics Ltd's latest results are concerning, showing a Q4 FY26 net sales increase of 15.26% but a year-on-year decline of 7.54%, alongside a net loss of ₹13.42 crores and a significant drop in profitability, indicating ongoing operational challenges and investor concerns.
Mangalam Drugs Q4 FY26: Mounting Losses Signal Deepening Operational Crisis
Mangalam Drugs and Organics Ltd. reported a devastating fourth quarter for FY26, with net losses widening to ₹13.42 crores—marking a staggering 22,466.67% year-on-year deterioration from a marginal profit of ₹0.06 crores in Q4 FY25. The micro-cap pharmaceutical company, with a market capitalisation of just ₹48.00 crores, saw its stock languish at ₹30.01 on May 15, down 62.74% over the past year and trading 68.34% below its 52-week high of ₹94.80.
When is the next results date for Mangalam Drugs and Organics Ltd?
The next results date for Mangalam Drugs and Organics Ltd is 14 May 2026.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 27 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and overall outlook.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 13 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 31.57, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.99% on 8 Apr 2026, with buyers queuing and no sellers willing to part with shares.
Mangalam Drugs Gains 2.29%: Circuit Limits Highlight Volatility and Investor Sentiment
Mangalam Drugs and Organics Ltd experienced a volatile week marked by sharp circuit hits on both ends, ultimately closing with a modest gain of 2.29% while the Sensex declined by 0.29%. The stock’s trading was characterised by intense selling pressure early in the week, followed by a strong rebound amid constrained liquidity and regulatory price limits, reflecting a complex interplay of investor sentiment and technical factors.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 May 2025. However, the analysis and financial metrics presented here reflect the company’s current position as of 02 April 2026, providing investors with an up-to-date view of its fundamentals, returns, and overall outlook.
Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 5% Gain — Buyers Queue, Sellers Absent
At Rs 28.50, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 5% on 1 Apr 2026, with buyers queuing and no sellers willing to part with shares.
Mangalam Drugs and Organics Ltd Locks at Lower Circuit With 4.92% Loss — Sellers Queue, No Buyers in Sight
At Rs 27.05, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 4.92% on 30 Mar 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.
Mangalam Drugs Falls 4.60%: Circuit Hits and Volatility Define the Week
Mangalam Drugs and Organics Ltd experienced a turbulent week marked by sharp price swings and circuit breaker hits, ultimately closing down 4.60% at Rs.28.41 compared to the previous Friday’s close of Rs.29.78. This decline notably outpaced the Sensex’s 1.46% fall over the same period, reflecting heightened volatility and investor caution amid mixed market signals and sector pressures.
Below All Moving Averages and Now at Lower Circuit: Mangalam Drugs and Organics Ltd Loses 3.9% in a Single Session
At Rs 28.43, sellers were still queuing — but there were no buyers willing to take the other side. Mangalam Drugs and Organics Ltd locked at its lower circuit of 5% on 27 Mar 2026, with unfilled sell orders and a frozen price, signalling persistent selling pressure in a micro-cap stock with limited liquidity.
Mangalam Drugs and Organics Ltd Locks at Upper Circuit With 4.16% Gain — Buyers Queue, Sellers Absent
At Rs 30.53, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Mangalam Drugs and Organics Ltd locked at its upper circuit of 4.16% on 24 Mar 2026, with buyers queuing and no sellers willing to part with shares.
Mangalam Drugs and Organics Ltd Hits Lower Circuit Amid Heavy Selling Pressure
Shares of Mangalam Drugs and Organics Ltd plunged sharply on 19 Mar 2026, hitting the lower circuit limit as intense selling pressure gripped the stock. The pharmaceutical micro-cap witnessed a maximum daily loss of 4.77%, closing at ₹29.16, reflecting a significant investor sell-off amid deteriorating market sentiment and weak technical indicators.
Mangalam Drugs and Organics Ltd is Rated Strong Sell
Mangalam Drugs and Organics Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 19 May 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 19 March 2026, providing investors with the latest insights into its performance and outlook.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
